Physician profile
Stephen E Baum
NPI 1083650485
$1,210.07
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $163 · 2021: $256 · 2022: $191 · 2023: $162 · 2024: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $664.66 | 2019-2024 | Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $113.97 | 2020-2023 | Entyvio |
| Steris Corporation | $76.20 | 2024 | |
| Janssen Biotech, INC. | $70.00 | 2020-2023 | Stelara, Simponi Aria, Simponi |
| Ucb, INC. | $46.06 | 2019-2020 | |
| Sandoz INC. | $34.54 | 2024 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $31.53 | 2023-2024 | Dupixent |
| Abbvie INC. | $29.91 | 2021-2022 | |
| Pfizer INC. | $29.07 | 2019-2022 | |
| Gilead Sciences, INC. | $23.06 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $19.95 | 2024 | Bylvay |
| Ferring Pharmaceuticals INC. | $18.99 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.68 | 2020 | |
| Olympus America INC. | $17.88 | 2024 | Visiglide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.57 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.